S&P 500
(0.05%) 5 250.89 points
Dow J
(0.00%) 39 762 points
Nasdaq
(-0.09%) 16 384 points
Oil
(1.82%) $82.83
Gas
(0.52%) $1.727
Gold
(1.25%) $2 240.40
Silver
(1.09%) $25.02
Platinum
(1.42%) $922.60
USD/EUR
(0.23%) $0.926
USD/NOK
(0.64%) $10.84
USD/GBP
(-0.05%) $0.791
USD/RUB
(0.12%) $92.55

Realtime updates for Terns Pharmaceuticals, [TERN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return 11.69%
SELL
50.00%
return -13.69%
Last Updated28 Mar 2024 @ 12:39

7.79% $ 6.64

SELL 62050 min ago

@ $6.86

Issued: 14 Feb 2024 @ 09:30


Return: -3.21%


Previous signal: Feb 9 - 15:54


Previous signal: Buy


Return: -0.72 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 12:39):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity...

Stats
Today's Volume 817 341
Average Volume 824 101
Market Cap 429.29M
EPS $0 ( 2024-03-25 )
Next earnings date ( $-0.350 ) 2024-05-20
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -5.23
ATR14 $0.0230 (0.35%)
Insider Trading
Date Person Action Amount type
2024-03-10 Kuriakose Emil Sell 0 Common Stock
2024-03-10 Kuriakose Emil Sell 280 000 Stock Option (Right to buy)
2024-03-10 Kuriakose Emil Sell 117 500 Stock Option (Right to buy)
2024-03-01 Burroughs Amy L. Buy 1 250 000 Stock Option (Right to buy)
2024-03-01 Burroughs Amy L. Buy 150 000 Restricted Stock Unit
INSIDER POWER
78.48
Last 96 transactions
Buy: 30 047 425 | Sell: 4 951 891

Volume Correlation

Long: 0.00 (neutral)
Short: -0.28 (neutral)
Signal:(41.701) Neutral

Terns Pharmaceuticals, Correlation

10 Most Positive Correlations
SVAC0.926
EMLD0.908
ARTEU0.905
CFFE0.905
PAIC0.898
LRMR0.898
GDST0.897
ARIZ0.896
CARG0.892
LQDA0.891
10 Most Negative Correlations
BCAB-0.929
ATAI-0.923
CUTR-0.923
SMFL-0.92
GMAB-0.919
MYSZ-0.919
SRAC-0.916
SPCX-0.908
VFF-0.906
NCBS-0.903

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Terns Pharmaceuticals, Correlation - Currency/Commodity

The country flag 0.44
( neutral )
The country flag -0.05
( neutral )
The country flag 0.00
( neutral )
The country flag 0.57
( weak )
The country flag 0.59
( weak )
The country flag 0.74
( moderate )

Terns Pharmaceuticals, Financials

Annual 2023
Revenue: $0
Gross Profit: $-881 000 (0.00 %)
EPS: $-1.270
Q4 2023
Revenue: $0
Gross Profit: $-220 000 (0.00 %)
EPS: $-0.290
Q3 2023
Revenue: $0
Gross Profit: $-222 000 (0.00 %)
EPS: $-0.420
Q2 2023
Revenue: $0
Gross Profit: $-217 000 (0.00 %)
EPS: $-0.250

Financial Reports:

No articles found.

Terns Pharmaceuticals,

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators